Another Drug Approved for Treating Chronic Hepatitis C

Sovaldi is the third drug with breakthrough therapy designation to receive FDA's approval.

The U.S. Food and Drug Administration on Dec. 6 approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus infection, stating in a news release that it is "the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon."

"Today's approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C," said Dr. Edward Cox, M.D., director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. The agency had approved Olysio (simeprevir) on Nov. 22.

Sovaldi is marketed by Gilead, based in Foster City, Calif.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Comply with OSHA’s Electronic Recordkeeping Requirements

    Collect relevant incident data and generate accurate OSHA 300, 300A, and 301 regulatory reports, including 300A CSV files for easy electronic submission to OSHA.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Industry Safe
comments powered by Disqus